CDK16

Across TCGA pan-cancer cohorts, CDK16 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CDK16’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CDK16 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CDK16 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

CCRCC, PDAC, and LUAD are the cancer types where CDK16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDK16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.203	.002	8	view →
PDAC	All	All	+0.261	.002	4	view →
LUAD	All	All	−0.103	.001	2	view →
LSCC	Female	II,III,IV	+0.188	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CDK16–CCRCC

Open the CCRCC breakdown →